Table 1 Demographic data of the ST-segment elevation myocardial infarction (STEMI) and control groups
From: Homocysteine is a bystander for ST-segment elevation myocardial infarction: a case-control study
| Â | STEMI | Control | p value |
|---|---|---|---|
Number, n | 56 | 17 | NA |
Age, yr | 58.1 ± 13 | 57.5 ± 11 | 0.854 |
Male, n(%) | 43(77) | 11(65) | 0.353 |
Hypertension, n(%) | 25(45) | 9(53) | 0.589 |
Diabetes, n(%) | 13(23) | 3(18) | 0.748 |
Dyslipidemia, n(%) | 23(41) | 8(47) | 0.781 |
Smoking, n(%) | 33(59) | 6(35) | 0.103 |
Stroke, n(%) | 7(13) | 1(6) | 0.672 |
Peripheral arterial disease, n(%) | 0(0) | 0(0) | NA |
End-stage renal disease, n(%) | 1(2) | 0(0) | 1.000 |
History of congestive heart failure, n(%) | 1(2) | 1(6) | 0.414 |
Family history of myocardial infarction, n(%) | 7(13) | 2(12) | 1.000 |
Body-mass index, kg/m2 | 25.1 ± 4 | 25.5 ± 6 | 0.835 |
Mortality, n(%) | 2(4) | 0(0) | 1.000 |
Regular B-vitamin supplements> 1 year, n(%) | 0(0) | 0(0) | NA |